siRNA therapy markedly reduces Lp(a) levels

Nature Reviews Cardiology, Published online: 16 November 2022; doi:10.1038/s41569-022-00813-7Olpasiran, a small interfering RNA (siRNA) that reduces lipoprotein(a) (Lp(a)) production in the liver, administered every 12 weeks induces a pronounced and sustained decrease in the plasma levels of Lp(a) in patients with established atherosclerotic cardiovascular disease, according to findings from the OCEAN(a)-DOSE trial.
Source: Nature Reviews Cardiology - Category: Cardiology Authors: Source Type: research